A biotech start­up breaks a 3-year si­lence, dis­play­ing a $65M raise and a next-gen ap­proach to PARP

Vic­to­ria Ri­chon’s team at Ri­bon Ther­a­peu­tics has been cruis­ing un­der the biotech radar for the past 3 years. But with a $65 mil­lion B round to dis­cuss with plans to move in­to the clin­ic, it’s time for a pub­lic dis­play on just what they’ve been work­ing on.

Over the past few years a whole group of play­ers has been ad­vanc­ing PARPs in­to the mar­ket for can­cer, throw­ing a mon­key wrench in a mech­a­nism cells use to re­pair dam­age. But while ri­vals stack up be­hind Lyn­parza from As­traZeneca and Mer­ck, Ri­bon is tak­ing it all one big step down the road.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER